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we review and comment on the data from ran-
domized studies so far reported and try to indicate
what could be next in this story. We also suggest
what may be the attitude we should take in our
everyday clinical practice.
Operable, high-risk breast cancer
(adjuvant therapy)
In the early 1990s phase II studies from several
centers and the European and American registries
showed a 60-65% disease-free survival (DFS) for
patients with high-risk operable BC at 4-5 years
post-transplant.13-15 Since these data appeared
better than those following standard dose thera-
py, several centers and co-operative groups began
phase III trials, comparing transplant to best avail-
able conventional therapy. Two early phase III ran-
domized studies from the Netherlands Cancer
Institute and the MD Anderson Cancer Center have
been published.16,17 No advantage of HDC has
emerged. However, both studies were designed to
detect an optimistic 30% difference in relapse-
free survival (RFS) between high-dose versus con-
ventional adjuvant therapy and were too small (81
and 78 patients randomized, respectively) to assess
smaller differences that cannot be excluded.18 In
this regard it is interesting to note that, in the sub-
sequent larger Netherlands Cancer Institute phase
III study, the HDC arm gave an overall survival (OS)
benefit of about 10% in the first 284 patients
studied, as detailed below in this article. After
excluding a misleading and unreliable trial,11 to
date 5 randomized studies with large patient
accrual have been either published or presented at
the 2000 and 2001 ASCO Meetings (Table 1).
The Scandinavian Study Group multicenter trial19
randomized 525 high risk primary BC patients to
receive 3 cycles of fluorouracil (5-FU), cyclophos-
Presentations of phase III trials evaluating highdose therapy (HDC) with autologous hemato-poietic progenitor cell transplantation (APCT)
for breast cancer (BC) at the recent American Soci-
ety of Clinical Oncology (ASCO) Meetings prompt-
ed us to comment on their results and review pre-
viously available clinical data. In the last decade,
we have observed very peculiar highs and lows in
the enthusiasm of clinicians for HDC with APCT
for treatment of BC. Early trials of HDC, based on
favorable laboratory and clinical indicators,1,2 ini-
tiated in the 1980s, suggested that HDC with APCT
might favorably affect the course of operable
high-risk and metastatic BC.3 Phase II studies cre-
ated positive expectations among physicians and
their patients, to such an extent that HDC with
APCT became widely used as a therapeutic option
also outside controlled trials. Simultaneously,
many phase III studies were initiated. The use of
blood cells instead of bone marrow for APCT4,5 sig-
nificantly reduced the morbidity and mortality
related to HDC6,7 and allowed the spread of this
procedure also outside specialized centers.
At the 1999 ASCO Meeting, findings from small
or prematurely reported randomized trials were
presented (abstracts 1-4, 161, Proceedings book).
These trials did not show unequivocally positive
results and their superficial consideration caused
a barrage of negative reports from media8 and
oncologists9 suggesting to many patients and
physicians final conclusions disparaging of this
therapy. The subsequent demonstration that the
South African adjuvant study10 was fraudulent11
had an additional detrimental effect on accrual to
ongoing randomized trials.12 At the 2000 and 2001
ASCO Meetings, new information was provided
from phase III trials of HDC for BC. In this article
phamide (CTX) and epirubicin (FEC) at standard dos-
es followed by HDC with the STAMP-V regimen (CTX
6 g/m2, thiotepa 500 mg/m2, and carboplatin 800
mg/m2) and APCT or nine cycles of FEC tailored to
individual tolerance (up to 1800 mg/m2 of CTX, 120
mg/m2 of epirubicin and 600 mg/m2 of 5-FU per
cycle) with granulocyte colony-stimulating factor
(G-CSF) support. The control arm was not given a
standard dose according to any widely accepted
definition. Patients in the non-HDC arm received
higher cumulative doses of alkylating agents and
had a higher incidence of treatment-related
leukemia and myelodysplastic syndromes. At a
median follow-up of less than 3 years (somehow
too short for any BC adjuvant trials) tailored FEC
resulted in an  improved DFS (p=0.04) with no dif-
ference in OS between the two study arms.
The Netherlands Cancer Institute multicenter tri-
al randomized 885 patients with more than 4
nodes at surgery to receive 5 courses of FEC versus
the same chemotherapy followed by HDC with CTX
6 g/m2, thiotepa 480 mg/m2 and carboplatin 1600
mg/m2 with APCT. The high dose regimen is similar
to the STAMP V regimen, but it contains a double
dose of carboplatin and the 3 alkylating agents are
given by short rather than continuous IV infusion.
The first analysis planned in the study protocol
evaluated the first 284 randomized patients20 and
found that DFS and OS were significantly improved
in the HDC arm (77% vs 62%, p=0.009 and 89%
vs 79%, p=0.039, respectively).
The CALGB-9082 multicenter phase III trial21
enrolled 785 patients with 10 or more positive axil-
lary nodes to receive 4 cycles of CTX, doxorubicin,
and 5-FU followed by either HDC with STAMP-I
(cyclophosphamide, cisplatin, and BCNU at 5625,
165, and 600 mg/m2, respectively) versus a single
cycle with the same drugs at intermediate doses
(900, 90, and 90 mg/m2, respectively). The inclusion
of this cycle in the control arm is evidence of the
investigator's desire for trial design symmetry. At a
median follow-up of 5.5 years both event-free and
OS were unexpectedly high (better than observed
in any prior study within the CALGB). The number
of relapses was higher in the standard arm than in
the HDC arm (167 versus 127, -31%), counterbal-
anced by an increased transplant-related mortali-
ty (TRM) in patients receiving HDC (7.4%). TRM
positively correlated with older patient age and
size of HDC activity of participating centers. In this
Editorial 901
haematologica vol. 86(9):september 2001
Table 1. Summary of randomized studies of HDC with APCT as adjuvant therapy for high-risk breast cancer.
Study group and leader investigatorrref. Patients Median follow-up Results Comment
(n) (years)
Netherlands Cancer Institute, S Rodenhuis16 81 4.5 No survival benefit Designed for detecting an optimistic 30% advantage;
small study; poor patient compliance with randomization
MD Anderson, G Hortobagyi17 78 4 No survival benefit Designed for detecting an optimistic 30% advantage;
small study; protocol treatment deviation; closed because of 
slow accrual.
Scandinavian Study Group, J Berg19 525 3 DFS favors control arm; Control arm not conventional tailored chemotherapy, 
OS same total dose of the non HDC arm higher; high incidence of 
MDS/AML in the control arm; longer follow-up required
Netherlands Cancer Institute, S Rodenhuis20 885, first 284 3.5 Significant improvement in DFS Evaluation of the whole study population required; 
patients evaluated and OS in the HDC arm TRM < 1%. Longer follow-up required 
CALGB, WP Peters21 785 5.5 No difference in EFS and OS 31% mortality reduction; high TRM, center- and age-depen
dent; control arm not conventional; patients < 50 years of age 
have better outcome (no statistical analysis provided so far).
The study requires longer follow-up
Milan Cancer Institute, AM Gianni22 382 5 EFS and OS same TRM < 1%; favorable trend in DFS in younger patients and
4-9 axillary nodes; short duration of the HDS arm.
The study requires longer follow-up
French PEGASE, HH Roche23 314 3 Significant improvement in DFS; Short follow-up; risk reduction for OS, DFS and 
no difference in OS. event free survivals.
study, in which the sample size was planned to
detect a 14% reduction of RFS at 5 years, DFS
favored HDC but did not reach statistical signifi-
cance. Furthermore, in the HDC arm women <50
years old had improved RFS. At the 2001 ASCO
Meeting results of statistical analysis of the latter
subgroup were not presented.
The Milan National Cancer Institute multicenter
phase III trial22 enrolled 382 patients with 4 or more
involved axillary nodes comparing adjuvant stan-
dard-dose (epirubicin 120 mg/m2 for 3 cycles fol-
lowed by CTX, methotrexate, 5-FU (CMF) for 6 cycles)
with sequential high-dose chemotherapy (HDS, CTX
7 g/m2; vincristine 2 mg and methotrexate 8 g/m2
with leucovorin rescue; epirubicin 120 mg/m2 q 14
days for 2 doses; and thiotepa 600 mg/m2 plus mel-
phalan 160-180 mg/m2 with APCT). The study was
designed with a power of 80% to detect a 15%
increase in progression-free survival (PFS) at 5 years
in the HDS arm. Treatment-related mortality was less
than 1%. PFS and OS at 5 years were similar in the
two treatment arms. Among the 112 patients
younger than 36 years, and the 147 patients with 4-
9 positive nodes, those in the HDS group showed a
trend for a DFS advantage (HR 0.66 and 0.69, respec-
tively). Since the 90% of patients in both treatment
arms received 5 years of tamoxifen, the authors sug-
gest that final analysis with a prolonged follow-up
is advisable. HDS and conventional treatment lasted
about 3 and 8 months, respectively. 
The French PEGASE multicenter phase III trial23
randomized 314 women with more than 7 positive
nodes at surgery to receive 4 cycles of FEC100, then
either no further chemotherapy or one cycle of high
dose CMA (CTX 120 mg/kg, mitoxanthrone 45
mg/m2, alkeran 140 mg/m2) followed by radiother-
apy and tamoxifen for positive hormonal receptor
menopausal women. Patients and tumor charac-
teristics were well balanced. With a median fol-
low-up of 39 months, 123 events and 63 deaths
occurred. In an intent-to-treat analysis, 3-year
rates for conventional and HDC arms were, respec-
tively, 55 and 70.8 % (p<0.003) for DFS and 84 and
86 % (p=0.33) for OS. HDC offers a significant risk
reduction of 22%, 43% and 39% (p=0.007) for OS,
DFS and event-free survivals, respectively. 
Locally advanced and inflammatory breast
cancer 
Stage III B and C BC accounts for about 5% of all
diagnoses but has a very high risk of distant recur-
rence. HDC with stem cell support has been utilized
within multimodality treatment programs of pri-
mary therapy. In general all these pilot/phase II
studies24-27 have shown  high rates of pathologic
response and apparent advantage in DFS rates.
However, the limited number of patients enrolled
and the lack of randomized trials do not allow con-
clusions to be drawn about survival.
Metastatic breast cancer
Pilot transplant trials in BC in the early 1980s
were initially conducted in metastatic disease and
demonstrated high response rates for patients with
measurable tumors.28,29 This translated into an
apparent improvement of survival compared with
that recorded in similar groups of patients treated
with conventional therapy. The observation that in
studies of HDC without induction therapy long-
term DFS could be produced in a percentage of
patients is of particular note. Indeed, in updated
data from Peters et al.,29,30 a small group (14%) of
poor-prognosis premenopausal patients who were
estrogen receptor-negative, and had visceral dom-
inant disease remain continuously disease-free
with a minimum follow-up of 11 years. The favor-
able initial results of HDC prompted several groups
to use this approach to treat women at relapse
after therapy for primary disease. A large number
of phase II HDC studies have now been reported.31-
37 Taken together the data indicate that a single
course of HDC will result in 30%-50% complete
responses (CR) and overall responses (OR) in
approximately 80% of patients with MBC. The
American Blood and Marrow Transplant Registry
(ABMTR) reported outcomes for HDC in metastat-
ic disease which are consistent with the reported
phase II data.15 Long-term DFS at 5 years for
women receiving HDC appears to be largely supe-
rior compared to that achieved by current stan-
dard chemotherapy.38,39 After excluding an early
randomized trial40 that was discovered to have not
been conducted in a scientifically acceptable man-
ner,41 4 studies have so far been released compar-
ing HDC with APCT with conventional therapies
(Table 2). Results of these studies are described in
the following paragraphs.
The Philadelphia Intergroup phase III trial42
enrolled, over a 7-year period, 513 patients to
receive CAF (no prior anthracycline therapy) or CMF
salvage chemotherapy followed by randomization
for those in CR or partial remission (PR) to receive
either a transplant using the STAMP V regimen or
maintenance CMF for up to 24 cycles (2 years of
chemotherapy) or until progression. With patients
dropping out of the study, refusing to be random-
ized or for other reasons, only 33% of the original
patients (184) were randomized. The randomiza-
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tion was unbalanced (101 patients to the HDC arm
and 83 to the CMF arm). Ten patients (13%) ran-
domized to the control arm actually received HDC
and three patients received no therapy. Because of
the intention-to-treat analysis, all of these were
analyzed as part of the CMF arm. In contrast, five
patients in the HDC arm received no therapy. The
Philadelphia trial demonstrated no difference in
DFS (9.6 months for HDC versus 9.0 months for
CMF), or OS (24 months vs 26 months). The con-
version rate for patients from PR to CR in the study
by HDC was extremely low; 6% in the HDC arm
and 9% in the CMF arm. These data are in contrast
to the usual results obtained in MBC using HDC.
Overall the results that have been obtained in this
study are below the standard achieved in prior and
contemporary studies. Planned cumulative dose in
the CMF arm exceeds that of the HDC arm. Infor-
mation about the quality of life and the costs of
each of the arms may prove useful in placing this
study in appropriate context since with similar out-
comes well informed patients may prefer a short
intense treatment modality to up to two years of
repetitive cycles of chemotherapy. 
In the Dukes’ study43 with a crossover design, 120
of 453 patients with MBC attaining CR with con-
ventional dose doxorubicin, 5-FU and methothrex-
ate were randomized to either immediate HDC with
STAMP-I versus STAMP-I at the time of relapse.
The authors reported that high-dose consolidation
significantly delayed relapse (in some cases, pre-
venting it altogether) in patients who were in
remission following conventional chemotherapy.
Patients who were randomly assigned to observa-
tion following conventional treatment, however,
frequently went back into remission after high-
dose salvage therapy at the time of relapse. A group
of 69 women with bone metastases only under-
went the same randomization with crossover to
HDC for women with conventional treatment at
time of relapse. A significant difference in DFS
favors HDC.44 Because of the crossover design of
the Dukes’ trials, OS for conventional versus HDC
cannot be compared.
The French PEGASE 04 multicenter phase III tri-
al45 randomized 61 patients with stage IV disease
in clinical response after four to six cycles of con-
ventional therapy to receive either HDC with CMA,
or two to four additional cycles of the same con-
ventional chemotherapy. Median DFS were 20 ver-
sus 35 months in the standard and HDC groups,
respectively (p=0.05). Similar results were seen in
OS with a median of 20 months in the standard
dose arm and 43 months in the HDC arm. Because
of small sample size, the data only approached sta-
tistical significance (p=0.06). At five years, the
relapse rates were nearly identical: 90.8% and
90.7%, respectively. 
The National Cancer Institute of Canada phase III
trial46 randomized 219 MBC patients achieving
response with first line treatment to receive 2-4
additional cycles of standard chemotherapy or 1-
2 cycles followed by HDC (CTX 6 g/m2, mitoxan-
throne 70 mg/m2, carboplatin 1800 mg/m2) with
stem cell rescue. Twenty-three of the 112 patients
randomized in the HDC arm never received trans-
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Table 2. Summary of randomized studies of HDC with APCT in patients with metastatic BC achieving response to convention-
al first line therapy.
Study group and leader investigator(ref.) Patient Median follow-up Results Comment
(n) (years)
Philadelphia-Intergroup, EA. Stadtmauer42 553/184 5 No difference in DFS and OS > 60% drop-out; poor conversion to CR; 13% patients in the 
control arm received HDC; low TRM
Dukes’ study. WP Peters43 425/120 9 Improvement in DFS OS not evaluable (crossover design); delayed HDC effective
high TRM
Dukes’ study (bone metastasis only), B Modan44 69 5 Improvement in DFS OS not evaluable (crossover design); high TRM
bone metastasis setting.
French PEGASE, JP Lotz45 61 5 Improvement in DFS, Small study
OS equivalent at 5 years
Cancer Institute of Canada, M Crump46 219 3 DFS prolonged, High TRM; high progression rate before transplantation
no difference in OS
plantation because of progression or other causes.
Seven treatment-related deaths were recorded, all
in the HDC arm (7.7%). DFS was significantly pro-
longed in the HDC arm while no differences in 3-
year OS could be documented.
The therapeutic value of HDC in perspective
Evaluation of mature data of HDC with APCT in
comparison with conventional chemotherapy
allows the following considerations:
1. in the adjuvant treatment of high-risk BC,
among the five large adjuvant trials reviewed in
this article (Table 1), two have shown an advan-
tage for HDC and one favors the control arm.
Two studies have shown favorable trends in cer-
tain subgroups of patients. In these studies a
longer follow-up is required before definitive
analysis can be completed;
2. in the treatment of metastatic BC, three out of
the 4 studies reviewed in this article (Table 2)
have shown significant differences in DFS in
favor of HDC. The delay in relapse for patients
treated with HDC could potentially offer a
longer off-therapy survival and possibly better
quality of life. Analyses of subsets of patients in
CR, PR or by metastatic sites are limited due to
the lack of statistical power because of insuffi-
cient number of patients;
3. in some studies the duration of HDC programs
is shorter than with conventional chemothera-
py.22,42 Thus, even considering similar disease
outcomes, one could argue that patients might
prefer a short intense treatment modality rather
than prolonged administration of conventional
chemotherapy.
Overall, no study with adequate follow-up has
shown HDC with APCT to be an inferior option. The
outcomes of these trials have been quite variable,
this partially depending on their heterogeneity. In
fact, they differ in terms of disease stage, type of
HDC regimen, intensity and duration of the control
therapy, and the schedule of events in relation to
induction. As an example, the randomized data
thus far show the STAMP-V regimen to be equiva-
lent to dose-escalated FEC or CMF administered
for two years while other regimens including
STAMP-I and CMA have shown superiority in cer-
tain outcome end-points over conventional treat-
ments. It should also be taken into consideration
that, in HDC programs, important therapeutic dif-
ferences might be missed if biological aspects are
ignored. It is well known, for example, that the dose
effect is more significant in 20-30% of patients
whose tumors overexpress Her2/neu.47
It must be remembered that almost 100% of
patients with MBC, and more than 50% of patients
with high-risk multinode positive disease will die
from cancer, despite partially successful conven-
tional treatment. As previously stated, high rates of
durable remission, never observed by convention-
al treatments, are provided by long-term follow-up
of studies of HDC. For these reasons continued
investigation of high-dose strategies is not only
advisable, but mandatory. Several randomized tri-
als of HDC are currently either ongoing or are
awaiting analysis.48 The SWOG 9623 trial bears
mentioning as it compares sequential dose-dense
chemotherapy (doxorubicin, paclitaxel, and CTX)
with standard doxorubicin plus CTX followed by
HDC (using either STAMP-I or STAMP-V) in patients
with 4 to 9 positive lymph nodes. This trial is par-
ticularly pertinent as it contains adjuvant taxane
therapy and 2 different approaches of HDC are
evaluated. Unfortunately, because of the alarmist
media coverage of the 1999 ASCO meeting, accru-
al to the study has dropped significantly. Recently,
growing interest has been observed for the repet-
itive HDC with APCT strategy in BC49,50 and other
solid tumors. Although promising, results so far
produced are preliminary and this approach is
under evaluation in randomized trials. Costs of the
multiple transplant procedure is also a matter of
debate.51,52 In addition, new technologies offer the
prospect of almost cancer-free autografts53 and
are under evaluation in prospective studies. Final-
ly, HDC can be used as a platform on which to add
novel therapies aimed at treating residual tumor.
Proof of principle for such approaches could well
occupy clinical researchers for many years.
Some have criticized the further development of
HDC based on a higher priority for molecular tar-
geted therapies.54 Although clinicians wait for more
effective, biologically based treatments for BC, few
currently exist. The monoclonal antibody trastuzu-
mab is effective in a subset of patients with tumors
overexpressing Her2-neu and is not likely to be suf-
ficiently effective as single agent.55 The develop-
ment and subsequent clinical evaluation of more
effective targeted therapies is taking several years
and, in general, they are not likely to replace stan-
dard therapies but rather be integrated into them.
Monoclonal antibodies or other biologically based
treatments including vaccines, biological response
modifiers and new drugs could be incorporated into
high-dose regimens, the latter being per se capa-
ble of remarkable and rapid tumor regression, for
their potential to eliminate minimal residual dis-
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ease. Stem cell transplant technology is already
used to deliver new biologically based therapies.56
Nevertheless, at the present time encouraging
results of phase II studies of cell vaccination ther-
apies for solid tumors still need either to be con-
firmed or compared to standard treatments in ran-
domized trials.
While the debate and research on HDC continue,
we simply have to wait for time to allow the full
analysis of ongoing studies and get some more
insight into novel therapeutic approaches in BC. In
the meantime what is the attitude we should take
when women with high risk or metastatic BC ask
for advice? Whenever possible patients should be
enrolled in well designed randomized trials. Outside
clinical studies we find that there is some evidence
from the studies presented in this article to support
proposing the HDC approach to selected, well
informed patients. 
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